A new once-weekly insulin, efsitora, may be just as effective as daily injections for adults with type 2 diabetes who are new to insulin therapy. In a 52-week clinical trial, efsitora matched the performance of daily insulin glargine in lowering blood sugar, with fewer dose adjustments and a lower risk of severe hypoglycemia.
Dr. Timothy Bailey, Founder and Site President at Headlands Research - AMCR Institute, co-authored the study.
Read more in The New England Journal of Medicine.